Future Directions for Pharmaceutical Policy in the New Era of High Cost Medicines

Sylvia Park; Eun-Ja Park

Full metadata record

DC Field	Value
dc.contributor.author	Sylvia Park
dc.contributor.author	Eun-Ja Park
dc.date.accessioned	2012-07-19T01:41:45Z
dc.date.available	2012-07-19T01:41:45Z
dc.date.issued	2012
dc.identifier.isbn	978-89-8187-873-3
dc.identifier.uri	https://repository.kihasa.re.kr/handle/201002/8684
dc.description.tableOfContents	CHAPTER 1 Introduction 3 Section 1. Background 3 Section 2. Purpose 4 Section 3. Contents and Methods 4 CHAPTER 2 Current State of high-cost medicines 9 Section 1. Definition of High-Cost Medicines 9 Section 2. Characteristics of High-Cost Medicines 13 Section 3. Current State of High-Cost Drug Market and Outlook 16 Section 4. Policy Issues Related to high-cost medicines 20 CHAPTER 3 High-Cost Medicines and Relevant Systems in Korea 29 Section 1. High-Cost Medicines in Korea 33 Section 2. Relevant Systems 36 CHAPTER 4 Policy Recommendations in the High-Cost Drug Era 55 Section 1. Insurance Coverage 49 Section 2. Appropriate Utilization 51 Section 3. Enhanced Evidence Development 54 CHAPTER 5 Conclusions 61 References 61
dc.format	application/pdf
dc.language	eng
dc.publisher	한국보건사회연구원
dc.publisher	Korea Institute for Health and Social Affairs
dc.rights	Attribution-NonCommercial-NoDerivs 2.0 Korea (CC BY-NC-ND 2.0 KR)
dc.rights	KOGL BY-NC-ND
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/2.0/kr/
dc.rights.uri	http://www.kogl.or.kr/info/licenseType4.do
dc.title	Future Directions for Pharmaceutical Policy in the New Era of High Cost Medicines
dc.type	Book
dc.type.local	Report
dc.type.other	Working Paper
dc.identifier.localId	Working Paper 2012-04
dc.subject.kihasa	식품/의약품